Plain-English translation of NCT06999707 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of radiation therapy with two immunotherapy medications called and for people with advanced hepatocellular carcinoma (a type of liver cancer) that cannot be surgically removed. While this medication combination is already approved as a first-line treatment for advanced liver cancer, it only helps about 1 in 5 patients. Researchers believe adding radiation therapy to the medication might help more patients benefit from the treatment.
The immunotherapy medication combination works for some patients, but not enough. Laboratory studies suggest that combining radiation with this treatment could strengthen the body's immune response against cancer cells, but this has never been properly tested in patients with liver cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive photon radiation therapy (a common type of radiation) directed at your liver cancer, along with regular infusions of the two immunotherapy medications. The trial will monitor your health closely through blood tests and imaging scans to measure how well the treatment works and to watch for side effects. The study is enrolling 45 patients, and researchers will track your response to treatment over time to understand whether this combination approach is safer and more effective than the medications alone.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Taiwan